Rapport Therapeutics, Inc. (RAPP) AI Stock Analysis

• Market Cap: $565.71M
• Dividend Yield: N/A
• Average Volume (3M): 152.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 69
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.68
• Shares Outstanding: 36,497,677
• 10 Day Avg. Volume: 170,018
• 30 Day Avg. Volume: 152,868
• PEG Ratio: 0.46
• Price to Book (P/B): 18.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.73
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.33K
• Enterprise Value/Ebitda: -1.62
• 1Y Price Target: $35.00
• Price Target Upside: 125.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 44 Neutral
• Price Target: ―

Rapport Therapeutics, Inc. faces significant challenges with no revenue and substantial operational losses despite strong equity financing and low leverage. Technical indicators point to a downward trend, and valuation is difficult to ascertain. Positive clinical trial results offer some optimism, but leadership changes contribute to uncertainty.

Positive Factors

Clinical Trial Progress

The Phase IIa trial of RAP-219 in refractory focal epilepsy has completed enrollment with 30 patients and topline results are expected.

Drug Efficacy

RAP-219's precise targeting of areas associated with seizure activity eliminates off-target toxicity observed in current anti-epileptic drugs.

Market Interest

RAPP over-enrolled the ph2a due to greater-than-expected patient demand, and they'll now be presenting data of 30 FOS-patients, suggesting strong interest and potential for the study.

Negative Factors

Drug Approval Challenges

The company outlined what it considers a successful result in the topline Phase IIa readout expected and hosted a fireside chat with KOL and trial investigator Jacqueline French, M.D., who expressed firm conviction in the trial's potential for disease improvement.

Earnings and Development Timeline

Rapport Therapeutics announced their earnings, confirming previously announced development timelines.

Rapport Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Rapport Therapeutics, Inc. (RAPP) is a biotechnology company focused on developing precision medicines to treat neurological disorders. By leveraging advanced drug discovery techniques, the company aims to create targeted therapies that address specific neural pathways associated with various conditions. Rapport Therapeutics operates in the biopharmaceutical sector, with a core emphasis on innovative research and development in neuroscience.

How the Company Makes Money

Rapport Therapeutics, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company engages in partnerships and collaborations with other pharmaceutical firms to co-develop and license its therapies, which can provide milestone payments and royalties. Additionally, Rapport may secure funding through grants and research agreements to support its drug discovery and development efforts. The company's financial growth is supported by strategic alliances and the successful advancement of its drug pipeline through clinical trials.

Rapport Therapeutics, Inc. Financial Statement Overview

Summary

Rapport Therapeutics, Inc. shows strong equity financing and low leverage, which supports its financial stability despite the absence of revenue and increasing operational losses. The biotech sector's nature, with its reliance on external financing for research, poses risks if funding sources change. Continued focus on innovation and achieving revenue milestones is critical for future financial health.

Income Statement

Rapport Therapeutics, Inc. has reported no revenue for the past three years, with increasing losses, as evidenced by the rising net loss from $10.65 million in 2022 to $78.31 million in 2024. This indicates a challenging revenue generation environment, common in early-stage biotech companies focused on research and development without commercial products.

Balance Sheet

The company maintains a strong equity position with stockholders' equity increasing from $19.51 million in 2022 to $305.43 million in 2024. The low debt levels, with a debt-to-equity ratio of approximately 0.005, suggest financial stability. However, the lack of revenue generation poses a risk to long-term sustainability if financing sources diminish.

Cash Flow

Operating cash flow has significantly deteriorated, with free cash flow going from -$3.53 million in 2022 to -$67.23 million in 2024. The heavy reliance on financing cash flows, notably a $221.63 million inflow in 2024, supports operations but highlights the potential cash flow challenges if external funding becomes scarce.

Breakdown	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00
Gross Profit	0.00	-112.00K	-15.00K
EBITDA	-77.47M	-34.66M	-10.35M
Net Income	-78.31M	-34.79M	-10.65M
Balance Sheet
Total Assets	314.93M	155.42M	31.60M
Cash, Cash Equivalents and Short-Term Investments	305.28M	147.56M	31.16M
Total Debt	1.48M	2.15M	0.00
Total Liabilities	9.51M	14.48M	12.10M
Stockholders Equity	305.43M	140.94M	19.50M
Cash Flow
Free Cash Flow	-67.23M	-28.82M	-3.53M
Operating Cash Flow	-64.83M	-27.18M	-3.24M
Investing Cash Flow	-170.14M	-78.86M	-5.28M
Financing Cash Flow	221.63M	145.14M	39.69M

Rapport Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RAPP, the sentiment is Positive. The current price of 15.5 is above the 20-day moving average (MA) of 13.69, above the 50-day MA of 12.02, and above the 200-day MA of 15.19, indicating a bullish trend. The MACD of 1.10 indicates Negative momentum. The RSI at 71.97 is Negative, neither overbought nor oversold. The STOCH value of 72.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RAPP.

Rapport Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRTC	58 Neutral	$463.17M	9.01	11.96%	―	43.67%	―
Sector *	56 Neutral	$6.14B	22.14	-28.61%	4.89%	10.73%	-32.66%
AUTL	54 Neutral	$713.26M	―	-49.91%	―	-14.16%	25.88%
ALT	51 Neutral	$347.95M	―	-57.28%	―	-95.12%	21.09%
RAPP	44 Neutral	$565.71M	―	-33.14%	―	―	―
CELC	44 Neutral	$532.02M	―	-115.39%	―	―	-4.14%
ORIC	43 Neutral	$1.01B	―	-48.45%	―	―	7.15%

Rapport Therapeutics, Inc. Corporate Events

Rapport Therapeutics Appoints New CMO Amid Phase 2a Updates

On March 3, 2025, Rapport Therapeutics announced the appointment of Jeffrey Sevigny as Chief Medical Officer and provided updates on its Phase 2a trials for RAP-219 in refractory focal epilepsy and bipolar mania. The company expects to report topline results for the epilepsy trial in the third quarter of 2025 and plans to initiate a trial for bipolar mania in the same period, with results anticipated in the first half of 2027. These developments are significant for Rapport’s operational focus and strategic positioning in the neuroscience market.